From the biotech boom to biotech bankruptcies, what is the current state of the D&O market for life sciences companies? What are the factors that we expect will continue in the year ahead? Join Rich Leavitt and Andrew Sousa, Alliant Life Sciences, as they welcome Steve Shappell, Alliant Claims & Legal, to discuss market stability, claims trends, recommended coverages for buyers and boards and current challenges including limited access to capital affecting directors and officers.